Pivotal ALPHA3 Trial Shows Cema-Cel Achieves 58.3% MRD Clearance, Significantly Outperforming Observation Arm
Summary
Allogene Therapeutics reported highly positive interim futility analysis results from its pivotal Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL). The cema-cel arm demonstrated a 58.3% minimal residual disease (MRD) negativity rate, significantly higher than the 16.7% in the observation arm, representing a 41.6% absolute difference. This data is crucial as MRD clearance is a strong predictor of relapse. Furthermore, the drug exhibited a favorable safety profile with no serious adverse events, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD). This strong efficacy and safety profile from a pivotal trial is a major catalyst for a clinical-stage biotech, suggesting cema-cel could be a highly competitive 'off-the-shelf' CAR T therapy and potentially re-rate the stock. Traders will closely watch for full study results and regulatory progress.
At the time of this announcement, ALLO was trading at $3.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $663.1M. The 52-week trading range was $0.86 to $2.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.